Feed INCY
IN

Incyte

INCY · NASDAQ

$123.89 -1.46% (-$1.83)
1M +0.54%
Market Cap $25.1B
P/E Ratio 15.57x
Div. Yield -
ROE 29.70%

Bulios Fair Price

$119.18

3.8% downside

Current Price

$123.89

Undervalued Fair Value Overvalued

According to Bulios Fair Price, INCY is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Moderate
6/9
Valuation
77 /100
Cheap
P/FCF 13.08x
P/E 15.57x
P/B 3.96x
Growth
85 /100
Growing
FCF growth 14.94%
EPS growth 61.56%
Book val. growth 5.75%
Profitability
100 /100
Strong
Op. margin 31.57%
Gross margin 92.62%
FCF margin 33.00%
Quality
94 /100
Excellent
ROA 20.48%
ROIC 22.92%
Asset turnover 0.74x
Debt
100 /100
Low
Int. coverage 847.54x
Debt/Equity 0.01x
Net debt/EBITDA -1.93x
Stability
68 /100
Stable
EPS volatility 2,416.72%
Beta 0.77x
Profitable years 5

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about INCY
Online

About the company

Incyte Corporation (INCY) is an American biopharmaceutical company specializing in the research, development, and commercialization of therapies focused on oncology and other serious diseases. The company is known for its strong emphasis on scientific research and innovation, leading to the discovery of new therapeutic possibilities. Incyte focuses on developing small molecule drugs and immunotherapies that have the potential to significantly improve patients' lives. Incyte Corporation (INCY) shares might be appealing to investors seeking involvement in the biotechnology sector with a focus on innovation and treatment of serious diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

William J. Meury

Employees

2,844

Headquarters

Wilmington

Upcoming events

27 OCT

Earnings

Upcoming earnings report

29d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.